|
answer text |
<p>The Department funds research into all aspects of human health, including prostate
cancer, through the National Institute for Health Research (NIHR) at the level of
£1 billion per year. The following table shows the NIHR’s programme expenditure specifically
prostate cancer since April 2018:</p><p> </p><table><tbody><tr><td><p>Award title</p></td><td><p>Total
award budget</p></td></tr><tr><td><p>A randomised controlled trial of Partial prostate
Ablation versus Radical Treatment (PART) in intermediate risk, unilateral clinically
localised prostate cancer</p></td><td><p>£ 2,677,446</p></td></tr><tr><td><p>Enzalutamide
for treating non-metastatic hormone-relapsed prostate cancer [ID1359]</p></td><td><p>£
65,625</p></td></tr><tr><td><p>A randomised controlled trial of TRANSrectal biopsy
versus Local Anaesthetic Transperineal biopsy Evaluation (TRANSLATE) of potential
clinically significant prostate cancer</p></td><td><p>£ 1,072,414</p></td></tr><tr><td><p>Darolutamide
with androgen deprivation therapy for treating non-metastatic hormone-relapsed prostate
cancer [ID1443]</p></td><td><p>£ 65,625</p></td></tr><tr><td><p>Olaparib for previously
treated, hormone-relapsed metastatic prostate cancer (ID1640)</p></td><td><p>£ 131,250</p></td></tr><tr><td><p>Perineal
biopsy devices for diagnosis of prostate cancer in people with suspected prostate
cancer</p></td><td><p>£ 175,219</p></td></tr><tr><td><p>A miniature tethered drop-in
laparoscopic molecular imaging probe for intraoperative decision support in minimally
invasive prostate cancer surgery</p></td><td><p>£ 869,105</p></td></tr><tr><td><p>Prostate
Liquid Biopsy Test for Risk Stratification of Prostate Cancer, preparation for CE
marking.</p></td><td><p>£ 205,098</p></td></tr><tr><td><p>Transforming management
of advanced prostate cancer: Increasing clinical productivity and capacity and empowering
men through digital health</p></td><td><p>£ 149,168</p></td></tr><tr><td><p>Further
development of and evidence generation for a precision dosing tool for optimising
chemotherapy dosing in advanced prostate cancer</p></td><td><p>£ 150,000</p></td></tr><tr><td><p>GlycoScore:
Superior prostate cancer diagnosis using a simple blood test</p></td><td><p>£ 150,000</p></td></tr><tr><td><p>Integrating
genetic testing into the prostate cancer pathway to more precisely guide care, treatment
and accelerate clinical trials</p></td><td><p>£ 3,001,779</p></td></tr><tr><td><p>SUrvivors'
Rehabilitation Evaluation after CANcer (SURECAN)</p></td><td><p>£ 2,447,636</p></td></tr><tr><td><p>Supported
exercise TrAining for Men with prostate caNcer on Androgen deprivation therapy – STAMINA</p></td><td><p>£
2,497,723</p></td></tr><tr><td><p>Endoscopically-delivered Purastat for the treatment
of haemorrhagic radiation proctopathy: a randomised feasibility study</p></td><td><p>£
225,720</p></td></tr><tr><td><p>Improving self and clinical management of comorbid
diabetes during cancer treatments: a qualitative interview study with patients and
clinicians to identify theory-based intervention targets, strategies and implementation
options</p></td><td><p>£ 149,784</p></td></tr><tr><td><p>A multicentre randomised
controlled trial (RCT) of a self-help cognitive behavioural therapy (CBT) intervention
to reduce the impact of hot flush and night sweat (HFNS) symptoms in men with prostate
cancer undergoing androgen deprivation therapy (ADT): MANaging symptoms during prostate
CANcer treatment (MANCAN2)</p></td><td><p>£ 348,659</p></td></tr><tr><td><p>The Prostate
Cancer Androgen Receptor Splice Variant 7 Biomarker Trial (The VARIANT trial) - A
multicentre feasibility study of biomarker-guided personalised treatment in advanced
prostate cancer.</p></td><td><p>£276,230</p></td></tr><tr><td><p>Improving outcomes
for men undergoing surgery for prostate cancer. A study to evaluate the feasibility
of a multicentre randomised controlled trial of frozen section technology to improve
oncological and functional outcomes at robotic radical prostatectomy.</p></td><td><p>£
249,302</p></td></tr><tr><td><p>Multimodal treatment for patients with prostate cancer:
a national study using existing electronic data.</p></td><td><p>£ 257,830</p></td></tr><tr><td><p>Total</p></td><td><p>£15,165,614</p></td></tr></tbody></table><p>
</p><p> </p><p>The NIHR also supports the delivery in the health and care system of
prostate cancer research funded by research funding partners in the charity and public
sectors. The NIHR Clinical Research Network has supported over 90 prostate cancer
related studies since April 2018, totalling £20.3 million.</p>
|
|